| Ytd | -82.38% | |
| 1y | -87.29% |
| Open | 0.13 | Prev Close | 0.07 | Low | 0.06 | High | 0.13 | Mkt Cap | 30.66M |
| Vol | 28.50M | Avg Vol | 9.18M | EPS | -0.37 | P/E | -0.20 | Forward P/E | -10.86 |
| Beta | 1.30 | Short Ratio | 1.70 | Inst. Own | 27.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.15 | 200-d Avg | 0.37 | 1yr Est | 6.33 |
SGMO News
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, i
SGMO explores strategic alternatives, ZOOZ considers complementing bitcoin strategy, Arcline acquire
RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Conse
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) s
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a ge
US stocks lower, Dow falls 100 points. Energy shares up 1%, communication services down 0.7%. Brinke
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a ge
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its s
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Announced in June, positive topline results from registrational STAAR study in Fabry disease, includ
Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 ce
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a ge
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a gen
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a gen
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a gen
Sangamo Therapeutics, Inc. ( SGMO ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Parti
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Conse
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated
https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-r
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte